Passage Bio (PASG) to Release Quarterly Earnings on Tuesday

Passage Bio (NASDAQ:PASG) is anticipated to announce its Q4 2025 results before the market opens on Tuesday, March 3rd. Analysts expect the company to announce earnings of ($2.19) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 5, 2026 at 9:30 AM ET.

Passage Bio Price Performance

Shares of PASG stock opened at $8.73 on Tuesday. The company has a market capitalization of $27.76 million, a PE ratio of -0.61 and a beta of 1.72. The firm’s 50-day moving average is $11.68 and its two-hundred day moving average is $9.19. Passage Bio has a 12 month low of $5.12 and a 12 month high of $20.00.

Insider Transactions at Passage Bio

In other news, CEO William Chou sold 4,076 shares of the stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $18.44, for a total transaction of $75,161.44. Following the sale, the chief executive officer owned 6,524 shares of the company’s stock, valued at approximately $120,302.56. This represents a 38.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Yiheng Capital Management L.P. purchased a new position in Passage Bio in the 4th quarter valued at approximately $405,000. Quadrature Capital Ltd acquired a new position in Passage Bio during the 4th quarter worth $148,000. Renaissance Technologies LLC increased its holdings in Passage Bio by 8.2% during the 4th quarter. Renaissance Technologies LLC now owns 109,089 shares of the company’s stock worth $1,287,000 after purchasing an additional 8,300 shares during the period. Geode Capital Management LLC raised its position in Passage Bio by 15.1% in the 4th quarter. Geode Capital Management LLC now owns 31,397 shares of the company’s stock valued at $371,000 after purchasing an additional 4,114 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in shares of Passage Bio in the 3rd quarter valued at about $188,000. Institutional investors and hedge funds own 53.48% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on PASG. Weiss Ratings reiterated a “sell (d-)” rating on shares of Passage Bio in a report on Monday, December 29th. Chardan Capital initiated coverage on Passage Bio in a research report on Tuesday, February 10th. They issued a “buy” rating and a $21.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.67.

Passage Bio Company Profile

Passage Bio is a clinical-stage biotechnology company focused on the development of gene therapies to treat rare, monogenic central nervous system and neuromuscular disorders. The company applies its in-house gene therapy platform to design and engineer adeno-associated virus (AAV)–based vectors that restore or replace defective genes, aiming to deliver durable treatments with a single administration.

The company’s lead programs include PBGM01, an AAV9-based therapy for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), which is conducting a first-in-human study to assess safety and potential therapeutic benefit.